What was Sanofi India's revenue in Q3 FY26?

Sanofi India reported revenue of ₹1,511 Cr in Q3 FY26, a — change year-over-year.

Did Sanofi India management deliver on previous promises?

Scorecard data is being built as historical quarters are processed.

Sanofi India Q3 FY26 Research Workspace: Revenue ₹1,511 Cr (—)

Q: What guidance did Sanofi India management give?

Partnership revenue fluctuations to continue through FY26: Management expects inventory phasing and frozen periods to cause quarterly volatility, with stabilization by end of FY26.

Revenue ₹1,511 Cr

EBITDA —

PAT — +4%

EBITDA Margin 21.5%

Duration 54 min

Read Time 1 min read

Financial stats pending filing verification

2-Minute Summary

✦ AI-Generated from Full Transcript

Sanofi India reported a mixed Q4 FY26 with domestic sales of ₹1,511 crore for FY25, driven by 11% YoY growth in the diabetes segment, led by insulin portfolio (Lantus, Toujeo, Soliqua). However, partnership revenue declined sharply to ₹153 crore in Q4 from ₹200 crore in Q3 due to inventory phasing and a frozen period. PAT grew 4% YoY for the full year, but EBITDA margin fell to 21.5%, an eight-quarter low, impacted by export decline and partnership volatility. Management expects partnership fluctuations to continue through FY26, with stabilization by year-end. Diabetes growth remains robust, with insulin volume accelerating +6% overall and +11% in Q4. Key risk: continued partnership revenue volatility could mask underlying business performance.

Risks3 trackedTranscriptfull text

Research workspace

Focused Modules

!Risks 3 risks

Risk Intelligence

Partnership revenue volatility

View Risks →

≡Transcript Full text

Call Transcript

Full transcript text is available on this route.

Read Transcript →

Quarter Snapshot

Insulin volume growth (full year) +6%

+6% YoY

Overall insulin volume growth for FY25, driven by Toujeo and Soliqua.

Insulin volume growth (Q4) +11%

+11% YoY

Accelerated momentum in Q4, indicating recovery from transformation.

Partnership revenue (Q4) ₹153 crore

-24% QoQ

Sharp drop from ₹200 crore in Q3 due to inventory phasing and frozen period.

Lantus market share (basal segment) 31%

flat YoY

Continued leadership in basal insulin segment despite GLP-1 competition.

Fast read

Guidance and risk preview

Top guidance Partnership revenue fluctuations to continue through FY26

Management expects inventory phasing and frozen periods to cause quarterly volatility, with stabilization by end of FY26.

Top risk Partnership revenue volatility

Quarterly fluctuations due to inventory phasing and frozen periods may persist through FY26, obscuring underlying growth.